Consensus statement

Access to disease modifying treatments for rheumatoid arthritis patients

Rheumatoid arthritis (RA) is a severe disease that leads to joint destruction, loss of quality of life, work disability and premature mortality, as well as significant costs to the patient and to the health care system. Although effective therapeutic regimens are currently available, many patients fail to respond to these treatments, fail to sustain an initial response, or suffer from significant toxicity necessitating withdrawal of treatment. Moreover, remission is rare and curative treatment unknown. It is clear, therefore, that new treatments are needed.

Patients and doctors wish the best possible treatment to be prescribed for RA. The highest responsibility of doctors is that towards their patients. However, in an environment of increasing costs for medical care, doctors must also be cognisant of issues related to the costs of newly available treatments. In this context, it is helpful to establish a consensus of worldwide experts for the rational and successful use of such new therapeutic agents, even though such a consensus is provisional and will change as new data become available.

The newly developed disease modifying anti-rheumatic treatments seem to be a significant advance in the therapeutic armamentarium for RA. The presently available evidence shows that these agents lead to a significant reduction in the signs and symptoms of RA, a decrease in acute phase proteins and an increase in health related quality of life. As with all newly developed compounds, the long term efficacy and long term side effects of these new agents are as yet unknown. A method for a systematic collection and analysis of long term data on all such agents and controls is strongly recommended.

The use of these new agents should be under the supervision of physicians who are experienced in the diagnosis and treatment of RA, including the use of immunomodulatory agents. In addition, they should be experienced in the clinical assessment of RA treatment, including efficacy and long term observation for potential toxicities related to these drugs.

Provisional consensus statement on TNF blocking agents in rheumatoid arthritis (March 1999)

Background
A consensus group to consider the use of TNF (tumour necrosis factor) blocking agents was formed by an organising committee constituted of rheumatologists from the Universities of Erlangen, Leiden, and Vienna in cooperation with a number of universities in the United States. Pharmaceutical support was obtained from a number of companies, but these institutions had no part in the decisions regarding the specific programme nor with regard to the participants or attendees at this conference.

The approximately 80 rheumatologists and bioscientists from 22 countries who attended the consensus conference were chosen from a worldwide group of people felt to have experience or interest in the use TNF blocking treatment for RA. Unfortunately, the number of attendees and participants were limited so that not everyone who might have been appropriate could be invited.

While a great deal of knowledge regarding the use of TNF blocking agents in RA is as yet unknown (long term effectiveness and toxicity, effect on structural damage, use in early RA, etc), it was felt that a provisional statement regarding their use in RA would be very useful.

After initial discussion in small groups, two large group discussions and repeated drafts allowed repeated input from all participants and we feel that this document represents a good provisional consensus for the use of TNF blockade in RA. We, further, feel that it should be changed as additional evidence is gathered, presented in scientific forums and debated.

Consensus

INDICATION
Patients who are candidates for TNF blocking agents should have active rheumatoid disease despite a full and adequate trial of one or more DMARDs. Individual patients differ in the aggressiveness of their disease and its concomitant structural damage, the effect of their disease on their quality of life and the symptoms and signs engendered by their disease. All of these factors must be examined when considering TNF treatment for that patient, as must the toxicity of previous DMARD use. TNF blocking agents can be added to pre-existing methotrexate treatment.

The use of TNF blocking agents should be under the supervision of physicians who are experienced in the diagnosis and treatment of RA, including the use of immunomodulatory agents. In addition, they should be experienced in the clinical assessment of RA treatment including efficacy and long term observation of RA for potential toxicities related to immunomodulatory drugs.

REASONS FOR DISCONTINUATION
TNF blocking agents, when given in adequate doses and sufficiently frequent dosing regimens, should lead to significant, documentable improvement in symptoms, signs and/or laboratory parameters within 8 to 12 weeks. If such improvement has not occurred within this time frame, alternative treatments or regimens should be considered.

WARNINGS
TNF blocking agents should not be started or should be discontinued when serious infections occur, such as septic arthritis, infected prosthesis, pyelonephritis, postoperative abscesses, osteomyelitis, sepsis, systemic fungal infections, listeria or mycobacterial infections, etc. Treatment should only be resumed if such infections have been completely healed and the risk of recurrence is low.

PRECAUTIONARY STATEMENTS
The effect of TNF blockade is unknown in the following situations:
1. Lymphoma, lymphoproliferative disease and, possibly, other malignancies.
2. Chronic viral infections such as HIV, hepatitis B or C.
3. During pregnancy or lactation.
ADDITIONAL COMMENTS

1 Rare cases of lupus-like disease have occurred in patients receiving TNF blocking agents and treatment should be stopped if there is clinical evidence of a lupus-like syndrome. There is thus far no evidence that RA patients who have positive ANA and/or ACL are susceptible to develop symptoms of drug induced lupus and treatment in this group of patients can probably be continued.

2 As TNF blocking agents are proved efficacious and their toxicity profile is demonstrated in patients with particular juvenile chronic arthritis, these treatments should be used in that population.

3 The safety of primary vaccinations and live-attenuated vaccines during TNF blockade treatment is not known. It is hoped that this observation for efficacy and safety. Further considerations when using TNF blocking agents in this disease must include cost issues and recognition that data in subpopulations are still being acquired. It is hoped that this statement, which is based upon the best evidence available at the time of its creation and modified by expert opinion, will facilitate the optimal use of these agents for our patients with RA.

4 The safety of sequential use of different TNF blocking agents is unknown, but cross reactivity is at least theoretically possible.

**Summary**

TNF inhibitors seem to be promising therapeutic agents for RA. The use of these new agents will require physicians experienced in the diagnosis, treatment and assessment of RA. These physicians will need to make long term observations for efficacy and safety. Further considerations when using TNF blocking agents in this disease must include cost issues and recognition that data in subpopulations are still being acquired. It is hoped that this statement, which is based upon the best evidence available at the time of its creation and modified by expert opinion, will facilitate the optimal use of these agents for our patients with RA.

D E FURST, F C BREEDVELD
G-R BURMESTER, L CROFFORD
P EMERY, M FELDMAN
J R KALDEN, A KAVANAUGH
E KEYSTONE, P E LIPSKY
R N MAINI, L MORELAND
J S SMOLEN, L VAN DE PUTTE
T VISCHER, M WEINBLATT
M WEISSMAN

representing the approximately 80 rheumatologists at the Advances in Targeted Therapies TNF Blockade in Clinical Practice.

Professor Michael Doherty acted as guest editor for this article.

Supported by unrestricted educational grants from: Amgen, Centocor, Inc, ImmunoGen Corp, Knoll AG, Schering Plough, Wyeth Ayers. None of the 17 primary authors are under retainer as consultants to sponsors interested in TNF-blocking treatment, although they may have received grants for research (basic and/or clinical) from the sponsor.

**Selected list of references**


Moreland LW, Baumgartner SW, Schi...